New hope for endometriosis? Plant-Based pill takes on hormone therapy
NCT ID NCT07164183
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a plant-based supplement (Indinol Forto, made from indole-3-carbinol) works as well as a standard hormone drug (Visanne, dienogest) for reducing pelvic pain in endometriosis. About 290 women aged 18-45 with surgically confirmed endometriosis will take one of the two treatments for 24 weeks. The main goal is to see if pain scores improve similarly in both groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indinol Forto (indole-3-carbinol) and Visanne (dienogest)
What this could lead to
If successful, this could offer a new non-hormonal option for managing endometriosis pain, potentially with fewer side effects than current hormone therapies.
What could go wrong
This is a non-inferiority trial, so it may only show that Indinol Forto is no worse than Visanne, not necessarily better. The open-label design (no placebo) could bias results, and the study is still recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
NOT_YET_RECRUITINGKazan', Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
NOT_YET_RECRUITINGMoscow, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
NOT_YET_RECRUITINGRostov-on-Don, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
RECRUITINGRyazan, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
NOT_YET_RECRUITINGSaint Petersburg, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
RECRUITINGSmolensk, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
NOT_YET_RECRUITINGTver', Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
RECRUITINGYaroslavl, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••